Singapore’s Prestige Biopharma has entered into a binding agreement for an exclusive partnership with Dr Reddy's Laboratories, which will be responsible for the supply and commercialization of Prestige’s proposed HD201 trastuzumab biosimilar rival to Herceptin across “select countries” in Latin America and Southeast Asia.
Dr Reddy’s will have exclusive rights to commercialize the proposed biosimilar across these countries, the exact details of which have yet to be made public